Skip to main content
IRLAB Therapeutics logo

IRLAB Therapeutics — Investor Relations & Filings

Ticker · IRLAB ISIN · SE0012675361 LEI · 549300JAT34LHEI0DH60 ST Manufacturing
Open in API
Filings indexed 157 across all filing types
Latest filing 2023-01-17 Earnings Release
Country SE Sweden
Listing ST IRLAB

About IRLAB Therapeutics

https://irlab.se/

IRLAB Therapeutics is a research and development company that discovers and develops novel treatments for neurodegenerative diseases, with a primary focus on Parkinson's disease and other central nervous system (CNS) disorders. The company's research originates from Nobel Prize-winning science and is driven by its proprietary Integrative Screening Process (ISP) platform. This systems pharmacology-based discovery engine utilizes an extensive database to generate a pipeline of drug candidates. The company's portfolio includes clinical-stage assets such as Mesdopetam (IRL790), in development for treating levodopa-induced dyskinesia (LIDs), and Pirepemat (IRL752), which is being developed to reduce falls and improve balance in patients with Parkinson's disease.

Recent filings

Filing Released Lang Actions
IRLAB announces top-line results from Phase IIb trial of mesdopetam (IRL790) in Parkinson’s disease
Earnings Release Classification · 98% confidence The document is titled "IRLAB announces top-line results from Phase IIb trial of mesdopetam (IRL790) in Parkinson's disease" and is explicitly labeled as a "Press Release". It details the results of a clinical trial, including primary and secondary endpoints, safety profiles, and future plans (webcast, further analysis). This content structure—announcing key results immediately—is characteristic of an Earnings Release (ER) or a general press release announcing significant corporate/clinical news. Since it is a direct announcement of financial/clinical results rather than a comprehensive annual report (10-K) or a detailed interim report (IR), the most fitting category is Earnings Release (ER). The document is not a transcript (CT), a formal regulatory filing like 10-K, or a presentation (IP). It is a direct announcement of results. FY 2023
2023-01-17 English
IRLAB rapporterar top-line resultat från Fas IIb-studien med mesdopetam (IRL790) i Parkinsons sjukdom
Earnings Release Classification · 98% confidence The document is a press release dated January 17, 2023, announcing the top-line results from a Phase IIb clinical study for the drug mesdopetam. It details the study's primary and secondary endpoints, safety profile, and future plans, including a webcast presentation scheduled for the next day. The text explicitly states, "IRLAB rapporterar top-line resultat från Fas IIbstudien..." and concludes with a section titled "Webbsändning för investerare, analytiker och media" which announces the upcoming presentation of these results. This structure—announcing results and immediately scheduling a follow-up event to discuss them—is characteristic of an Earnings Release (ER) or a general announcement of significant news. Since the content is a detailed summary of clinical trial results, which is a major corporate event, it fits best under the Earnings Release (ER) category, which covers initial announcements of periodical/significant results. It is not a full Annual Report (10-K), a Call Transcript (CT), or just a Report Publication Announcement (RPA) because it contains the actual substantive results, not just a notice that a report is available. The presence of contact information and the statement about being required to publish under EU market abuse regulation further confirms its nature as a formal corporate disclosure of material information. FY 2023
2023-01-17 Swedish
Nomination committee in IRLAB appointed ahead of annual general meeting 2023
AGM Information Classification · 95% confidence The document explicitly discusses the appointment of members for the 'nomination committee ahead of the annual general meeting (AGM) 2023'. This committee is responsible for proposing candidates for the board, which is a key preparatory step for the AGM. While it relates to governance and the AGM, the core subject is the composition of a committee related to the AGM process. The closest specific category is 'AGM Information' (AGM-R), as it details preparations for the upcoming meeting. It is not a full report (10-K, IR), a management change (MANG), or a proxy statement (PSI), but rather specific information directly tied to the AGM event structure.
2022-11-15 English
Valberedningen utsedd inför IRLAB:s årsstämma 2023
Board/Management Information Classification · 99% confidence The document is a press release dated November 15, 2022, announcing the appointment of the members of the Nomination Committee (Valberedningen) for IRLAB Therapeutics AB's Annual General Meeting (AGM) in 2023. This announcement concerns the preparatory steps and governance structure related to the upcoming AGM, specifically regarding the committee responsible for nominating board members. This topic falls under corporate governance and preparation for the AGM. While it relates to the AGM, it is not the AGM presentation itself (AGM-R) or the proxy materials (DEF 14A/PSI). It is an announcement about the composition of a governance body related to the AGM. Given the options, 'Governance Information' (CGR) is the most appropriate fit as it deals with internal rules and board structure/nomination processes, which is a core component of corporate governance. It is not a general regulatory filing (RNS) because CGR is a more specific fit for nomination committee composition.
2022-11-15 Swedish
Interim / Quarterly Report 2022
Interim / Quarterly Report Classification · 100% confidence The document is titled 'Delårsrapport januari – september 2022' (Interim Report January – September 2022) for IRLAB Therapeutics. It contains comprehensive financial statements, including income statements, cash flow, and balance sheet data for the specified period, as well as management commentary on clinical trials and business strategy. It is a substantive financial report for a period shorter than a full fiscal year, fitting the definition of an Interim/Quarterly Report. 9M 2022
2022-11-09 Swedish
Interim / Quarterly Report 2022
Interim / Quarterly Report Classification · 100% confidence The document is titled 'Interim report January – September 2022' and contains comprehensive financial statements, including a balance sheet, income statement, cash flow analysis, and management commentary for the specified period. It is a substantive financial report rather than an announcement or a summary, fitting the definition of an Interim/Quarterly Report (IR). 9M 2022
2022-11-09 English

Browse filings by year

7 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.